This clinical study involving 178 COVID-19 patients revealed that carriers of IFNL3 and IFNL4 minor alleles are less likely to progress from mild to moderate COVID-19, that is, to develop COVID-19-related pneumonia. This evidence concerns the gene IFNL4 and pneumonia.